Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

WideCells strengthens management and advisory team as it embarks on a “new period of growth”

WideCells has brought in three new non-execs, created a Scientific Advisory Committee and appointed WG Partners as joint broker
doctor discussing stem cell treatment
WideCells offers various stem cell-related services, including insurance, education and storage and processing

As part of its transition from product development into a revenue-generative company, stem cell services provider WideCells Group PLC (LON:WDC) has beefed up its management and advisory team.

The London-listed group has added Peter Presland, Malcolm Glaister and Zakaria Aziz to its board as non-executive directors. Presland will be WideCells’ new chairman after the company confirmed Graham Hine has retired from the role.

WATCH: WideCells strengthens management and advisory team

The three new additions will all “bring a wealth of corporate experience”, WideCells said in Thursday’s statement.

Alongside the new board additions, WideCells has also created a Scientific Advisory Committee which will identify and advise the board on new developments within the stem cell sector.

The committee, which will be chaired by professor Tristan Mckay, will also help manage all research work for the group.

‘A new period of growth’

“With three divisions now operational and starting to generate revenues, we are about to embark on a new period of growth and development as we look to build our operational reach on an international scale, increase our client base, and ultimately transform the value profile of our company,” said chief executive João Andrade.

READ: WideCells Group formally inks revenue generating overseas deal

“We have welcomed three new board members, who bring a wealth of corporate knowledge and experience in the insurance, medical and financial industries, which will be invaluable to us as we target new markets and seek new commercial agreements to facilitate the roll-out of our stem cell services.

“To support this new board, and in line with our commitment to maintaining operational excellence and being at the fore of our field, we have also created a new Scientific Advisory Committee, which brings together some of the best brains in stem cell technology and regenerative medicine.

READ: WideCells expands its reach to Spain

“The committee's unrivalled knowledge and prestigious network of contacts will I believe provide us with a number of exciting growth opportunities.”

WideCells also said it had appointed WG Partners as its joint broker as it looks to raise its institutional profile.

View full WDC profile View Profile

WideCells Group Timeline

Related Articles

1528305384_Untitled-design-(3).jpg
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
cells
July 30 2018
Life science generally is developing at an incredible speed, says Joe Anderson

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use